Please choose your preferred booking method
Reported side effects are typically mild and transient: Localized injection site reactions, including redness or mild irritation
Tirzepatide, a dual GIP/GLP-1 receptor agonist, may also offer more favorable muscle preservation profiles, although further studies are needed
Soon the plan will require a $25 monthly copay for the Flyte program effectively a copay for anyone who is on a GLP-1 for weight loss
The TRIUMPH trial program documented observations across multiple dose cohorts
Patients may only receive retatrutide through: Approved clinical trials registered with the MHRA and listed on the ISRCTN or ClinicalTrials.gov registries The MHRA Early Access to Medicines Scheme (EAMS) or compassionate use programmes, which allow access to promising unlicensed medicines for patients with serious conditions where no adequate alternative exists however, no such route is currently in place for retatrutide , and patients should not assume access is available outside of a formal trial It is strongly advised that patients do not attempt to source retatrutide through unregulated online pharmacies or grey-market suppliers